FIELD: medicine.
SUBSTANCE: present disclosure relates to methods of treating breast cancer in a patient, involving administering to the patient a therapeutic combination containing elacestrant or a pharmaceutically acceptable salt thereof and abemaciclib or a pharmaceutically acceptable salt thereof. Present invention also relates to methods of treating ER + and HER2 breast cancer in a patient, which provide a longer progression-free survival time compared to other types of treatment.
EFFECT: disclosed is elacestrant in combination with abemaciclib in women suffering breast cancer.
20 cl, 4 ex, 6 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2747228C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| METHODS FOR TREATMENT OF OVARIAN CANCER | 2017 |
|
RU2772432C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2745678C2 |
| METHODS OF TREATING CANCER | 2016 |
|
RU2737496C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| METHODS AND COMBINATIONS OF KAT6 INHIBITORS FOR TREATING CANCER | 2021 |
|
RU2833058C1 |
| COMBINATIONS OF TGFβ INHIBITORS AND CDK INHIBITORS FOR TREATMENT OF BREAST CANCER | 2019 |
|
RU2784852C2 |
